Emerging Prognostic Markers Continue to Improve Myeloma Treatment

Share this content:
Newly-discovered and future biomarkers are likely to help oncologists give an accurate prognosis and to prescribe more effective treatment for patients with multiple myeloma.
Newly-discovered and future biomarkers are likely to help oncologists give an accurate prognosis and to prescribe more effective treatment for patients with multiple myeloma.

In 2015, the U.S. Food and Drug Administration (FDA) approved 4 new therapies for the treatment of multiple myeloma. In addition to the number of novel therapies under development for multiple myeloma, researchers are beginning to understand how the disease works, which will increase the number of prognostic markers that can be used to provide information about outcome, according to a review published in the British Journal of Haematology.1

Prognostic markers for myeloma now include a range of features such as patient fitness, disease biology, genetic lesions, radiological features, and depth of response.

“Based on the available prognostic markers, we use the information to counsel our patients regarding their prognosis and treatment options,” Henry Fung, MD, FRCPE, vice chair of hematology at the Fox Chase Cancer Center, and director of the Fox Chase Cancer Center-Temple University Hospital Bone Marrow Transplant Program in Philadelphia Pennsylvania, told Cancer Therapy Advisor.

Known Prognostic Markers

Age is a strong prognostic factor for patients with myeloma, but ongoing research shows that it does not directly affect outcomes. Age may, however, affect the intensity of treatment selected for a patient's disease. For example, fitness for stem cell transplantation may be more important than age, according to the review.2

A patient's disease biology, including proliferation rate, can also affect prognosis. One study showed that a high proliferation index was associated with a longer overall survival, compared with a proliferation rate of less than 1% S-phase plasma cells.3

Genetic lesions present in the myeloma can also affect prognosis. Multiple studies show that translocation (4;14) confers poor prognosis.4,5,6

As more of these prognostic markers are discovered, researchers continue to study how they affect disease outcomes.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs